Evidence map›Paper›PMID 33308315›Full record

ArticleActa neuropathologica communications2020

Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.

Ming Li, Guoping Li, Juri Kiyokawa, Zain Tirmizi, Leland G Richardson, Jianfang Ning, Saumya Das, Robert L Martuza, Anat Stemmer-Rachamimov, Samuel D Rabkin and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. FAPExperimental & molecular medicine · 2026
    Article
  4. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.International journal of molecular sciences · 2024
    Review
  19. Theranostics · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ming LiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Guoping LiCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Juri KiyokawaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Zain TirmiziDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Leland G RichardsonDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Jianfang NingDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Saumya DasCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Robert L MartuzaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA.
Anat Stemmer-RachamimovDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Samuel D RabkinDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA. rabkin@mgh.harvard.edu.ORCID 0000-0003-2344-2795
Hiroaki WakimotoDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA. hwakimoto@mgh.harvard.edu.ORCID 0000-0001-8225-241X
Harvard University · US

Funding

GENETICALLY ENGINEERED VIRUSES FOR BRAIN TUMOR THERAPYR01NS032677 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI MARTUZA, ROBERT L · 1994 to 2022
$9.0M
Novel oncolytic virotherapy for brain tumorsR21NS103187 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WAKIMOTO, HIROAKI · 2017 to 2018
$464k
NIH HHS R01CA16072NIH HHS R21 NS103187NINDS NIH HHS R01 NS032677
6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) are activated fibroblasts constituting the major stromal components in many types of cancer. CAFs contribute to hallmarks of cancer such as proliferation, invasion and immunosuppressive tumor microenvironment, and are associated with poor prognosis of patients with cancer. However, in glioblastoma (GBM), the most common and aggressive primary malignant brain tumor, our knowledge about CAFs or CAF-like stromal cells is limited. Here, using commonly accepted CAF markers, we characterized CAF-like cell populations in clinical glioma specimens and datasets along with mouse models of GBM. We found that tumor-associated pericytes marked by co-expression of fibroblast activation protein α (FAP) and PDGFRβ represent major stromal cell subsets in both human GBM and mouse GBM models, while a fraction of mesenchymal neoplastic cells also express FAP in patient tumors. Since oncolytic viruses can kill cancer cells and simultaneously modulate the tumor microenvironment by impacting non-neoplastic populations such as immune cells and tumor vasculature, we further investigated the ability of oncolytic viruses to target GBM-associated stromal cells. An oncolytic adenovirus, ICOVIR15, carrying ∆24-E1A and an RGD-fiber, infects and depletes FAP+ pericytes as well as GBM cells in murine GBM. Our study thus identifies FAP+/PDGFRβ+ pericytes as a major CAF-like stromal cell population in GBM, and highlights the unique property of this oncolytic adenovirus to target both GBM cells and GBM-associated stromal FAP+ cells.

Indexed as

Oncolytic VirusesAnimalsCancer-Associated FibroblastsDisease Models, AnimalEndopeptidasesFibroblast Activation Protein AlphaGlioblastomaHumansMembrane ProteinsMiceOncolytic VirotherapyPericytesReceptor, Platelet-Derived Growth Factor betaStromal CellsTumor MicroenvironmentEndopeptidasesFibroblast Activation Protein AlphaMembrane ProteinsReceptor, Platelet-Derived Growth Factor betaFAPGlioblastomaOncolytic virusPericytesTumor-associated fibroblasts

Identifiers

PMID33308315
PMCPMC7730751
OpenAlexW3112371012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.